Actually, as I type this, INO is worth $103.41M. Last I checked it is still loosing money, and it is a risky stock not suitable for many investors. It MIGHT have some significant success stories which in turn MIGHT make it a $5 or even a $10 stock; however other companies MIGHT provide better therapies for the markets INO is targeting. Take HEP-C, INO has a strong candidate but lately the Gilead HEP-C entry is making fast, profound, progress. There might not even be a market for the INO HEP-C product if the Gilead product is superior. As for universal flu therapies, please do your homework.
Plus the other 2 forgot to mention cervical cancer and hepatitis B. In hepatitis B there were killer "T-cells" found on the liver to kill the virus , when normally no T-cells survive on the liver to eradicate the disease, that's huge. Also in cervical cancer " Killer T-cells" were found destroying the cancerous cells. They are already designing phase III for cervical cancer vaccine , so they know the killer T-cells will do their job. DD is definitely needed on this and we all did it already! plus in the Luekimia all 14 patients in the CML arm saw positive antigen response in all subjects 100%!